Summary
Victoria Gray, the first person to receive an experimental CRISPR treatment for sickle cell disease in 2019, is now living a life free from severe pain and transfusions. Her successful treatment demonstrated the potential of gene editing and contributed to the 2023 approval of Casgevy, the first CRISPR-based therapy for the disease.